CERT · Certara, Inc. · Stock research

Current Thesis

One correction to the frame carried since early August, because it changes what the tape was reacting to: the FY2026 range was reaffirmed at the 2026-08-04 Q2 print, not revised down a second time. The release carries revenue $367–382M (0–4% growth), adjusted EBITDA margin 29–31%, adjusted diluted EPS $0.31–0.36 and 155–157M fully diluted shares. So the gap that opened to $6.87 in the premarket on 2026-08-04 — roughly 16% under the $8.18 prior close

The leg an investor is buying is self-help arithmetic on a flat top line. A reduction in force of roughly 5% of the global workforce carries approximately $13M of expected run-rate savings, including stranded costs from the divested medical and regulatory writing unit. The $100M repurchase program was completed — and the board authorized a further $50M with no expiration. Software revenue reached $48.8M (+4%) with software bookings $50.7M (+9%). The 2026-07-07 NVIDIA agentic-framework partnership over the Simcyp engine sits on top as unpaid-for optionality.

The narrative is maturing, dated 2026-08-07 → 2026-08-21. The recovery held for two more weeks and added about 2.8%, but there has been no fresh headline since the 08-04 print, RSI(14) sits at 55.2 rather than extended, and the next dated company event that resolves anything is the Q3 report around 2026-11-03. Attention arrived on 08-04; it has not expanded since.

Bullish and bearish views on Certara, Inc.

The model's bull view on Certara, Inc. (CERT), in brief: The guide held under pressure (2026-08-04): revenue $367–382M, adjusted EBITDA margin 29–31%, adjusted diluted EPS $0.31–0.36 reaffirmed alongside a revenue miss. The bear view: The shrinking half is nearly half the business: services revenue $44.5M, down 3% YoY, with services bookings $47.6M, down 6% YoY. Both cases follow in full.

Bull Case

• The guide held under pressure (2026-08-04): revenue $367–382M, adjusted EBITDA margin 29–31%, adjusted diluted EPS $0.31–0.36 reaffirmed alongside a revenue miss. A reaffirmation delivered on a miss is a harder datapoint than one delivered on a beat.
• Quantified cost takeout, first carried in Q3: approximately 5% of the global workforce cut, weighted to overhead, for approximately $13M of run-rate savings (Q2 release, 2026-08-04). Adjusted EBITDA was $26.2M in Q2, down 3% YoY — the cost programme is the bridge to the 29–31% margin guide.
• Float is shrinking with cash, not diluting: 12,377,833 shares repurchased for $98.21M completed the prior authorization, and $50M more was approved on 2026-08-04. Fully diluted share guidance of 155–157M for FY26 compares with 152.54M shares outstanding reported on 2026-08-07.
• Software is the growing half: software revenue $48.8M (+4% YoY) and software bookings $50.7M (+9% YoY) in Q2 2026, the mix the May 2026 reorganization into MID3 and ACE was built around.
• well under the 2026-08-21 close of $8.43.
• The AI link is infrastructure, not a banner: the 2026-07-07 NVIDIA partnership places agentic frameworks over the Simcyp PBPK engine and regulatory datasets used by the FDA and other agencies.

Bear Case

• The shrinking half is nearly half the business: services revenue $44.5M, down 3% YoY, with services bookings $47.6M, down 6% YoY. Total bookings of $98.3M grew 1%.
• Reported profitability is negative: net loss from continuing operations of $6.1M in Q2 2026 against $1.5M of net income in Q2 2025; diluted EPS $(0.04). Simply Wall St's Q2 summary cites a total-company net loss of $55.27M once discontinued operations are included.
• The sell-side marks the stock at or below spot: Barclays raised its target to $7.50 from $6.50 on 2026-08-05 at Equal Weight; Simply Wall St reported an August 2026 consensus target of $8.71 against the 2026-08-21 close of $8.43. There is little published upside cushion above the market.
• Finance leadership is still temporary: Faiz Mohammed has served as interim CFO since 2026-07-15, after John E. Gallagher III resigned effective 2026-07-14, and signed the Q2 10-Q certification in that capacity on 2026-08-04. Commercial leadership also turned over — Julien Perrier became Chief Commercial Officer effective 2026-08-01 following the departure of President and CCO Leif Pedersen, with Eric Jahn named CIO.
• A disclosure had to be corrected: the company amended a statement made on the 2026-08-04 call about the divested regulatory and medical writing unit's 2025 adjusted EBITDA, putting it at approximately $23M excluding corporate expense, per TipRanks' 2026-08 report of the correction. Management said reported results and the 2026 outlook were unaffected.
• The move is a repair, not a breakout: the 2026-08-21 close of $8.43 sits 38.0% below the $13.6 52-week high, with a three-month price change of +60.9% off a washed-out low.

Setup & Price Structure

• Reference close 2026-08-21: $8.43. RSI(14) 55.2 — mid-range, neither extended nor oversold. Distance below the 52-week high of $13.6 is 38.0%; three-month price change of +60.9%.
• The structure to watch is the post-print shelf: closes of $8.13 on 2026-08-06 and $8.20 on 2026-08-07, built directly off the 2026-08-04 gap that printed $6.87 premarket and recovered to roughly $7.20 intraday. Two subsequent weeks added about 2.8% without giving that shelf back.
• Positioning observables, stated as observables: the consensus target of $8.71 sits roughly 3% above the last close and the most recent single-firm target on the wire ($7.50, Barclays, 2026-08-05) sits below it; the company is a buyer of its own shares under a $50M authorization rather than an issuer into strength; there is no earnings date inside 30 days; retail-sentiment coverage has not clustered around the name since the 07-07 NVIDIA headline, and the two Benzinga items on that date are the most recent name-specific wire coverage in the 30-day window.
• What is absent matters: no confirmed insider purchase or sale in the public record reviewed here, and no new sell-side initiation since the print.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-confirmed investor event. The Q2 Form 10-Q was filed 2026-08-04, concurrent with the release, and the Q2 13F deadline of 2026-08-14 has passed. The 30-day window is empty of scheduled guidance events.
• ~2026-09-21 (est.): Certara's own events listing shows a company-hosted event at the Cambridge Innovation Center, Cambridge MA. Scientific/user programming, not a guidance or capital-markets event — it resolves nothing in the numbers.
• ~2026-11-03 (est.): Q3 2026 results — the first quarter carrying the ~$13M of run-rate savings and the first clean ex-divestiture comparison.
• 2026-11-14: Q3 13F deadline, which shows whether BlackRock's 11.60% stake held through the print.

Elapsed catalysts

• Undated, any session: an 8-K naming a permanent CFO. The search has been open since 2026-06-11. (passed 76d ago)

What Would Change Our Mind

The structure that carries the read is the $8.13–$8.20 shelf built on 2026-08-06 and 2026-08-07 and held through 2026-08-21; the level that says the repair failed is the print-day recovery low. A daily close below $7.20 surrenders the entire post-print recovery off the 2026-08-04 gap and puts the $6.87 premarket print back in play.

On fundamentals, three observables would break the self-help read independently of price: FY26 revenue guided below $367M or adjusted EPS below $0.31 at the Q3 report (~2026-11-03, est.), which would make this the third downward revision of 2026; adjusted EBITDA margin printing under the 29% floor of the reaffirmed guide despite a completed reduction in force, which would mean the ~$13M was absorbed rather than banked; or software bookings growth decelerating below the +9% posted in Q2 2026, which removes the one line that is compounding.

A fourth, softer condition: the narrative flipping to saturated without a bookings inflection — mainstream coverage arriving on the AI-partnership angle while services bookings stay negative — would mean the bid is headline-sourced. Conversely, a permanent CFO named before the Q3 print and repurchases visible under the new $50M authorization in the Q3 10-Q would extend the current read rather than end it.

Correlation Notes

• Trades with the small-cap life-science tools and CRO complex and with biotech funding proxies; software is 52% of Q2 revenue ($48.8M of $93.3M), so small-cap software multiple compression transmits as well.
• The 2026-07-07 NVIDIA partnership means AI-in-drug-discovery headlines can bid the shares independent of bookings — a channel that opened in July and has not been retested.
• Market capitalization was $1.25B on 152.54M shares at the 2026-08-07 close. At that scale, buyback demand under the $50M authorization and index/13F rebalance flow are material to the tape in a way they are not for larger comparables.
• Guidance revisions in this group cluster: pharma R&D budget commentary from larger tools names is a leading read on the services line that has now declined for consecutive quarters.